Skip to main navigation Skip to search Skip to main content

Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer

  • Pietro Scilipoti
  • , Mattia Longoni
  • , Mario de Angelis
  • , Paolo Zaurito
  • , Aleksander Ślusarczyk
  • , Francesco Soria
  • , Benjamin Pradere
  • , Wojciech Krajewski
  • , David D'Andrea
  • , Andrea Mari
  • , Francesco del Giudice
  • , Renate Pichler
  • , José Daniel Subiela
  • , Gautier Marcq
  • , Andrea Gallioli
  • , Luca Afferi
  • , Riccardo Mastroianni
  • , Giuseppe Simone
  • , Simone Albisinni
  • , Laura S. Mertens
  • Ekaterina Laukhtina, Katharina Oberneder, José Luis Rodríguez Elena, Javier Aranda, Alfonso Lafuente Puentedura, Jorge Caño Velasco, Roberto Contieri, Rodolfo Hurle, Keiichiro Mori, Piotr Radziszewski, the European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group
  • IRCCS Ospedale San Raffaele
  • Vita-Salute San Raffaele University
  • Medical University of Warsaw
  • University of Turin
  • La Croix du Sud Hospital
  • Wrocław Medical University
  • Medical University of Vienna
  • University of Florence
  • University of Rome La Sapienza
  • Innsbruck Medical University
  • Hospital Ramon y Cajal
  • Université de Lille
  • Autonomous University of Barcelona
  • Kantonsspital Luzern
  • IRCCS Istituti fisioterapici ospitalieri - Istituto Regina Elena
  • University of Rome Tor Vergata
  • Netherlands Cancer Institute
  • Hospital Universitario de Cáceres
  • Hospital General Universitario Gregorio Marañon
  • IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
  • The Jikei University School of Medicine
  • Karl Landsteiner Institute of Urology and Andrology
  • University of Texas Southwestern Medical Center
  • Cornell University
  • Charles University
  • Sorbonne Université

Research output: Contribution to journalArticleAcademicpeer-review

113 Downloads (Pure)

Abstract

Objective: To assess the oncological outcomes of patients with high-risk (HR) and very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) treated with upfront radical cystectomy (RC) vs Bacillus Calmette–Guérin (BCG) instillations from a contemporary European multicentre cohort. Patients and Methods: We conducted a retrospective analysis of 1491 patients diagnosed with HR- or VHR-NMIBC from a European multicentre database between 2015 and 2024. Patients were included if they received either upfront RC or at least five doses of BCG. A 1:1 propensity score matching (PSM) according to clinically relevant variables was applied. Progression was defined as muscle-invasive or metastatic disease. Cumulative incidence plots and multivariable competing risk regression models addressing cancer-specific mortality (CSM) were fitted. Results: Among the 1221 patients with HR- (n = 1221 [90%]) or VHR-NMIBC (n = 121 [10%]), 87 (7.1%) underwent upfront RC. The median follow-up was 2.6 years. After PSM (87 vs 87 patients), the 5-year CSM rate was similar in patients treated with BCG (13%) vs their upfront RC counterparts (16%) (hazard ratio: 1.77, 95% confidence interval [CI] 0.66–4.73; P = 0.3). Of the 1134 patients who initially received BCG, 73 (6.6%) eventually required delayed RC, with 34 (47%) progressing to muscle-invasive bladder cancer before delayed RC. The 3-year CSM rate was comparable in upfront RC (13%) vs delayed RC (11%) among non-progressing patients (P = 0.3). However, patients who progressed before delayed RC had worse 3-year CSM relative to those who did not (13% vs 31%, hazard ratio: 0.32, 95% CI 0.13–0.83; P = 0.018). Conclusion: Within a European cohort of patients with HR- and VHR-NMIBC, upfront RC was rarely performed. Patients treated with BCG did not exhibit a CSM disadvantage relative to their upfront RC counterparts. After matching, long-term CSM was similar between BCG therapy and upfront RC. Delayed RC, led to worse outcomes if performed after progression, but matched upfront RC when performed before progression, underscoring importance of timely surgery.
Original languageEnglish
Pages (from-to)47-54
Number of pages8
JournalBJU international
Volume136
Issue number1
Early online date2025
DOIs
Publication statusPublished - Jul 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bacillus Calmette–Guérin
  • high risk
  • non-muscle-invasive bladder cancer
  • survival analysis
  • upfront radical cystectomy
  • very high risk

Fingerprint

Dive into the research topics of 'Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer'. Together they form a unique fingerprint.

Cite this